DrugPatentWatch Database Preview
Drugs in Development Information for Apabetalone
» See Plans and Pricing
What is the drug development status for Apabetalone?
Apabetalone is an investigational drug.
There have been 6 clinical trials for Apabetalone.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2015.
The most common disease conditions in clinical trials are Cardiovascular Diseases, Atherosclerosis, and Myocardial Ischemia. The leading clinical trial sponsors are Resverlogix Corp, PPD, and Medidata Solutions.
There are eighteen US patents protecting this investigational drug and two hundred and thirty-five international patents.
Summary for Apabetalone
| US Patents | 18 |
| International Patents | 235 |
| US Patent Applications | 42 |
| WIPO Patent Applications | 27 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2015-10-01) |
| Vendors | 69 |
Recent Clinical Trials for Apabetalone
| Title | Sponsor | Phase |
|---|---|---|
| Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study | Steeve Provencher | Early Phase 1 |
| Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease | Resverlogix Corp | Phase 1/Phase 2 |
| A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis | Resverlogix Corp | Phase 1/Phase 2 |
Clinical Trial Summary for Apabetalone
Top disease conditions for Apabetalone
Top clinical trial sponsors for Apabetalone
US Patents for Apabetalone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Apabetalone | Start Trial | Pharmaceutical compositions for substituted quinazolinones | Resverlogix Corp. (Calgary, Alberta, CA) | Start Trial |
| Apabetalone | Start Trial | Compositions and therapeutic methods for the treatment of complement-associated diseases | Resverlogix Corp. (Calgary, Alberta, CA) | Start Trial |
| Apabetalone | Start Trial | Anti-inflammatory agents | Resverlogix Corp. (Calgary, Alberta, CA) | Start Trial |
| Apabetalone | Start Trial | 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, MI) | Start Trial |
| Apabetalone | Start Trial | Nitric oxide-releasing prodrug molecule of substituted quinazolines | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (Linhai, CN) SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD (Shanghai, CN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Apabetalone
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Apabetalone | Australia | 2012330885 | 2031-11-01 | Start Trial |
| Apabetalone | Canada | 2851996 | 2031-11-01 | Start Trial |
| Apabetalone | China | 103945848 | 2031-11-01 | Start Trial |
| Apabetalone | Denmark | 2773354 | 2031-11-01 | Start Trial |
| Apabetalone | European Patent Office | 2773354 | 2031-11-01 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
